EAM
DYN icon

Eventide Asset Management’s Dyne Therapeutics DYN Stock Holding History

Eventide Asset Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-680,305
Closed -$13.3M – 285
2025
Q4 		$13.3M Buy
+680,305
New +$12.9M 0.21% 128
2025
Q1 		– Sell
-332,277
Closed -$7.83M – 232
2024
Q4 		$7.83M Hold
332,277
– – 0.14% 142
2024
Q3 		$11.9M Sell
332,277
-152,723
-31% -$6.08M 0.21% 112
2024
Q2 		$17.1M Buy
+485,000
New +$14.1M 0.29% 100

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Eventide Asset Management's DYN Position: Q1 2026 in Review

Eventide Asset Management sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 680,305 shares — an estimated $13.3M sold.

Eventide Asset Management first reported a position in DYN in Q2 2024 and held it in 4 quarters. The position peaked at $17.1M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Eventide Asset Management reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Eventide Asset Management sold 680,305 Dyne Therapeutics shares in Q1 2026, an estimated $13.3M.
  • Eventide Asset Management first reported a position in Dyne Therapeutics in Q2 2024 and held it in 4 quarters.
  • Eventide Asset Management's Dyne Therapeutics position peaked at $17.1M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.